SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is trending due to heightened community speculation surrounding a potential supply shock, upcoming exchange burns, and ongoing legal developments. Investors are actively discussing the possibility of a major recovery, with many sharing long-term price predictions and strategies for navigating market volatility.

LUNA is the native token of the Terra blockchain, a decentralized platform designed to host applications and provide financial tools. Following a transition from Terra Classic, the new Terra chain was established through a community-led governance proposal to focus on a decentralized economy without a stablecoin. As the foundational asset of the protocol, LUNA functions as the engine for the network where value moves as users pay gas fees to interact with decentralized applications. Its primary value proposition lies in its ability to scale rewards for stakers as developer activity and transaction volumes grow within the ecosystem.  The network maintains security through a Proof of Stake system using the Tendermint consensus mechanism, where 130 independent validators compare transactions to ensure the integrity of the blockchain. Users who do not want to run their own node can delegate their tokens to these validators to help record and verify data. To ensure accountability, the protocol employs slashing, a penalty that removes a small portion of staked tokens if a validator misbehaves or goes offline.  Originally created by Terraform Labs, the project has evolved into a community-governed model where independent developer groups and users maintain the protocol. Terraform Labs currently manages a claims portal for users impacted by previous network events as part of ongoing legal and bankruptcy proceedings. The token serves multiple roles, including paying for gas fees to interact with dApps , providing voting power for governance proposals , and earning rewards through a fixed 7% annual inflation rate.

Terra 2.0

Terra 2.0 (LUNA) is currently sparking intense debate within the crypto community, driven by ongoing legal developments surrounding the founder and speculation regarding the project's long-term viability. Investors remain polarized, with some closely monitoring potential governance and ecosystem upgrades while others express skepticism, often drawing comparisons to past market volatility and drawing parallels to Terra Classic (LUNC).

TerraClassicUSD (USTC) was originally launched as an algorithmic stablecoin within the Terra ecosystem, designed to maintain a peg to the US dollar through an automated market-Module mechanism with LUNA (now LUNC). However, following the collapse of the Terra ecosystem in May 2022, the core stabilizing mechanism was disabled, and USTC lost its peg to the US dollar.  Since then, USTC has been a freely traded digital asset, with its price determined purely by market supply and demand. It no longer functions as a stablecoin, nor does it have an active peg-maintenance mechanism.  USTC remains an integral part of the Terra Classic ecosystem, where it continues to be used for various purposes, including DeFi applications , gas fees and trading. Unlike traditional fiat-backed assets, USTC’s value fluctuates based on market conditions and community participation.

TerraClassicUSD

TerraClassicUSD is gaining momentum as investors react to ongoing ecosystem governance proposals, active token burn initiatives, and optimistic speculation regarding a potential repeg. The community is closely monitoring legal developments and potential regulatory shifts, with many traders focused on volume-driven price movements and increased staking activity within the broader Terra Luna ecosystem.

ProShares Trust - ProShares Ultra 7-10 Year Treasury 2x Shares

ProShares Ultra 7-10 Year Treasury

ProShares Ultra 7-10 Year Treasury (UST) is seeing active discussion as investors weigh its role in macro hedging against broader bond market volatility and central bank policy uncertainty. Community sentiment remains split, with traders monitoring how shifting interest rates and evolving fiscal conditions impact the ETF's performance relative to other safe-haven assets.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing increased community chatter as traders weigh the upcoming Goliath mainnet launch against persistent skepticism regarding its long-term utility and past price volatility. While some participants are aggressively accumulating in anticipation of institutional adoption, others remain vocal about the project's lack of confirmed commercial partnerships and recurring patterns of speculative price swings.

$ORDI : first token deployed on Bitcoin Ordinals, with a 21 million supply. $DOGI : first token deployed on Dogecoin Ordinals, with a 21 million supply. The First DRC-20 token in the history

dogi

The DRC-20 token DOGI is gaining significant traction as community members emphasize the growth of the Doginals ecosystem and upcoming platform developments. Investors are actively discussing the token's relationship to the Dogecoin network and its potential as a memecoin play alongside established BRC-20 standards.

Constellation Energy Corp. engages in the generation, supply, and marketing of clean electricity, and renewable energy products and solutions. The firm also offers wholesale energy, retail products and services. It operates under the following geographical segments: Mid-Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT), and Other Power Regions Segment. The company was founded in 1960 and is headquartered in Baltimore, MD.

Constellation Energy Corporation

Constellation Energy Corp

Constellation Energy is trending as investors weigh potential federal regulatory shifts impacting power pricing alongside its critical role in meeting massive electricity demand from AI data centers. Community discussions remain focused on its position as a primary beneficiary of nuclear-powered grid infrastructure, despite recent market volatility and debates over the valuation impact of proposed grid auction changes.

Hubbell, Inc. engages in the designing, manufacturing, and sale of electrical and electronic products for non-residential and residential construction, industrial, and utility applications. It operates through the Electrical Solutions and Utility Solutions segments. The Electrical Solutions segment manufactures and sells wiring and electrical, lighting fixtures, and controls for indoor and outdoor applications as well as specialty lighting and communications products. The Utility Solutions segment is involved in the design, manufacture, and sale of electrical distribution, transmission, substation, and telecommunications products. The company was founded by Harvey Hubbell II in 1888 and is headquartered in Shelton, CT.

Hubbell Inc.

Hubbell is trending as a critical pick-and-shovel play for the AI power trade, with investors highlighting its role in the data center infrastructure buildout and essential grid modernization efforts. The community is focused on the stock's strong order backlogs and consistent growth, positioning it as a structural beneficiary of the ongoing transition to AI-driven electrical demand.

Alchemy Pay

Alchemy Pay is seeing heightened community discussion driven by anticipation of its upcoming L1 blockchain mainnet and ongoing regulatory expansion, with investors actively debating its long-term potential compared to similar payment-focused tokens. While some users express frustration over stagnant price action and supply unlocking, bulls are highlighting recent partnerships and broader infrastructure development as key catalysts for future growth.

Chip

CHIP is seeing intense debate as investors weigh strong AI infrastructure narratives against concerns over insider dumping and price volatility. While some community members are betting on a recovery supported by lock-up periods and potential institutional partnerships, others remain skeptical, framing the recent price action as a classic pump-and-dump cycle.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pacira (PCRX) Q1 Earnings Miss Estimates

Pacira (PCRX) delivered earnings and revenue surprises of -1.64% and +0.58%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Iovance Biotherapeutics (IOVA) to Post Earnings on Thursday

Iovance Biotherapeutics (NASDAQ:IOVA) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...

Regeneron (REGN) Surpasses Q1 Earnings and Revenue Estimates

Regeneron (REGN) delivered earnings and revenue surprises of +11.18% and +4.88%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Equities Analysts Offer Predictions for IOVA Q1 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Investment analysts at HC Wainwright cut their Q1 2026 EPS estimates for Iovance Biotherapeutics in a report issued on Wednesday, April...

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.4% - Here's What Happened

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 7.4% - Time to Sell...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Hold" by Brokerages

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) have been given a consensus rating of "Hold" by the twelve analysts that are covering the stock, MarketBeat reports. Two...

<ul class="summary-bullets"><li>Jefferies had predicted that IOVA could see a 5%-15% move on Replime’s drug getting rejected.&nbsp;</li><li>According to Chardan analyst Geulah Livshits, RP1’s rejection is a positive for Iovance's Amtagvi's near-term competitive position.</li><li>Iovance story "remains centered on" Amtagvi's sales acceleration and margin expansion in 2026, according to Jefferies.</li></ul>Shares of Iovance Biotherapeutics Inc. (IOVA) garnered retail attention on Friday in light of an aspiring rival’s drug failing to get the nod from the U.S. Food and Drug Administration.IOVA shares closed down 8% on Friday, surprising retail investors and analysts alike. Jefferies had predicted that IOVA could see a 5%-15% move on Replimune’s drug getting rejected.Earlier on Friday, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/repl-stock-dives-after-fda-refuses-approval-for-skin-cancer-drug/cZJ0Kb3RIto">refused</a> to approve Replimune’s (REPL) investigational melanoma drug RP1. The agency said in a letter to the company that the data submitted by Replimune as part of its application seeking approval of the drug is “insufficient to conclude substantial evidence of effectiveness” in the treatment of unresectable advanced cutaneous melanoma.Iovance’s Amtagvi cellular therapy is already approved as a treatment for people with previously treated melanoma that has spread or cannot be removed by surgery. The drug was granted accelerated approval in February 2024. The company recorded Amtagvi revenue of about $220 million for the full year 2025 in the U.S.<h2 class="st-heading-2">How Did Retail Traders React?</h2>A Stocktwits user expressed surprise at the stock closing down on the good news.<stembedurl>https://www.stocktwits.com/KingCuerv0/message/649991039</stembedurl>Yet another echoed the sentiment.<stembedurl>https://www.stocktwits.com/lebranjames/message/649990274</stembedurl>Another user opined that the stock may be down over concerns about FDA raising the bar for trials.<stembedurl>https://www.stocktwits.com/mlftt/message/649991395</stembedurl>Yet another user sounded optimism for clarity on sentiment around the stock on Monday. &nbsp;“Good news after good news lately, don’t let the price action tell you otherwise,” they said.<stembedurl>https://www.stocktwits.com/Morrito23/message/649985521</stembedurl>Overall retail sentiment around IOVA jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels. Retail chatter around IOVA rose 75%, according to platform data.<h2 class="st-heading-2">Analyst Take</h2>According to data from Koyfin, eight of the 11 analysts covering IOVA rate it ‘Buy’ or higher, while three rate it ‘Hold’. There are no ‘Sell’ ratings of the stock.The average 12-month price target on the stock is $9, representing a potential upside of about 144%.According to Jefferies analyst Andrew Tsai, the rejection for RP1 means one less competitor for Iovance in the near term though Replimune was “technically not an overhang.” Iovance story "remains centered on" Amtagvi's sales acceleration and margin expansion in 2026, he said. The analyst has a ‘Buy’ rating and $12 price target on the shares.Chardan analyst Geulah Livshits also kept &nbsp;a ‘Buy’ rating on Iovance Biotherapeutics (IOVA) with a $16 price target after Replimune (REPL) update. RP1’s rejection is a positive for Iovance's Amtagvi's near-term competitive position, the analyst told investors in a research note. However, the firm added that more direct competition from cell therapies "could be on the horizon" in 2027.<a href="https://stocktwits.com/symbol/IOVA">IOVA stock</a> has gained 21% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cue-stock-on-track-for-best-day-in-history-why-is-retail-optimistic/cZJ0N5KRItC">CUE Stock On Track For Best Day In History — Why Is Retail Optimistic?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the IOVANCE BIOTHERAPEUTICS logo is displayed on the screen of a tablet computer. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why

Earlier on Friday, the FDA refused to approve Replimune’s investigational melanoma drug RP1, which was a likely contender for Iovance’s Amtagvi. 

Equity

Earlier on Friday, the FDA refused to approve Replimune’s investigational melanoma drug RP1, which was a likely contender for Iovance’s Amtagvi. 


Iovance Biotherapeutics' (IOVA) Buy Rating Reiterated at Chardan Capital

Chardan Capital reissued a "buy" rating and set a $16.00 target price on shares of Iovance Biotherapeutics in a report on Friday...

Promising Biotech Stocks To Follow Today - April 10th

Danaher, Vertex Pharmaceuticals, Iovance Biotherapeutics, argenex, and Moderna are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies whose primary business is developing, manufacturing, or commercializing bi...

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Continue higher

Sideways action

Retreat lower

What’s your read on the market for next week?

Stocktwits

Stocktwits Polls

Investors are bracing for upcoming earnings with high stakes on whether management will deliver 'remarkable' growth or repeat last year's volatility.

Bullish sentiment hinges on the belief that the company's platform tech makes it a prime candidate for a lucrative big pharma acquisition.

Shareholders are voicing intense frustration toward leadership over communication transparency and the impact of frequent share dilution.

Traders are closely watching competitors like SMMT and REPL to gauge relative strength in the oncology sector and potential market leadership.

Market participants are debating whether heavy options activity at the 3.50 strike is intentionally suppressing the stock price ahead of key announcements.

Current Price	$3.40
Prev Close	$3.36
Open	$3.37
Dividend Yield	0.00%
50-Day Moving Average	$3.77
Beta	1.69
Avg. Volume	14.58M
PE Ratio	-3.03

52-Week High	$5.63
52-Week Low	$1.64
Market Capitalization	$1.52B
EPS (Annual)	-$1.09
Price to Book	2.00
Revenue Per Employee	$270,258.46

IOVA
Iovance Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IOVA News

IOVAIovance Biotherapeutics Inc